LBPH Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 4.64%
Insider Buying (Last 12 Months): $2,482.00
Insider Selling (Last 12 Months): $98,571,692.16

Longboard Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Longboard Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal Insider BuyingTotal Insider Selling

Longboard Pharmaceuticals Share Price & Price History

Current Price: $59.98
Price Change: Price Increase of +0.02 (0.03%)
As of 12/2/2024 09:00 PM ET

This chart shows the closing price history over time for LBPH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Longboard Pharmaceuticals Insider Trading History

See Full Table
Insider Selling at Longboard Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Longboard Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Longboard Pharmaceuticals (NASDAQ:LBPH)

63.28% of Longboard Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LBPH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$107Mbought$61MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
Longboard Pharmaceuticals logo
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Read More on Longboard Pharmaceuticals

Today's Range

Now: $59.98
Low: $59.98
High: $60.03

50 Day Range

MA: $59.88
Low: $59.50
High: $59.98

52 Week Range

Now: $59.98
Low: $3.60
High: $60.03

Volume

655,700 shs

Average Volume

1,113,743 shs

Market Capitalization

$2.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1

Who are the company insiders with the largest holdings of Longboard Pharmaceuticals?

Longboard Pharmaceuticals' top insider investors include:
  1. Randall Kaye (CMO)
  2. Arena Pharmaceuticals Inc (Major Shareholder)
Learn More about top insider investors at Longboard Pharmaceuticals.